

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2019/165379 A1

(43) International Publication Date
29 August 2019 (29.08.2019)

(51) International Patent Classification:

A61K 31/137 (2006.01) *A61P 25/24* (2006.01)
A61K 31/485 (2006.01) *A61P 25/28* (2006.01)
A61P 25/00 (2006.01) *A61P 25/30* (2006.01)
A61P 25/18 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2019/019445

(22) International Filing Date:

25 February 2019 (25.02.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/634,718 23 February 2018 (23.02.2018) US
62/794,469 18 January 2019 (18.01.2019) US
62/809,480 22 February 2019 (22.02.2019) US

(71) Applicant: **AXSOME THERAPEUTICS, INC.** [US/US];

25 Broadway, 9th Floor, NEW YORK, NY 10004 (US).

(72) Inventor: **TABUTEAU, Herriot**; 25 Broadway, 9th Floor,

New York, NY 10004 (US).

(74) Agent: **JOHNSON, Brent A.** et al.; Maschoff Brennan,

100 Spectrum Center Drive, Suite 1200, Irvine, California
92618 (US).

(81) Designated States (*unless otherwise indicated, for every*

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every*

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION

(57) Abstract: Described herein are dosage forms of enantiomerically enriched (*S*)-bupropion or enantiomerically enriched (*R*)-bupropion. The (*S*)-bupropion or the (*R*)-bupropion may be deuterium enriched, or may have natural isotopic abundance. These dosage forms may be administered, either fed or fasted, to treat a condition recited herein, to achieve a certain pharmacokinetic parameter of a bupropion or a metabolite of a bupropion, and/or to enhance dextromethorphan plasma levels.

WO 2019/165379 A1